Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Two hundred seventy-five cranial computed tomography (CT) scans performed on 179 patients with malignant melanoma were reviewed. Of the 101 patients with confirmed cerebral metastases, CT demonstrated lesions in 93. In 72% of these, areas of increased attenuation were present in the precontrast scan. These lesions also enhanced after contrast infusion. There was a direct correlation between the extent of bleeding in the neoplasm and the density of the metastasis, at least 20% red blood cells per high power field were consistently present within lesions of increased attenuation. Cerebral metastases were occasionally associated with subdural or intracranial hemorrhage. Meningeal melanomatosis was recognized by CT only when associated with adjacent parenchymal metastases. In nine (11%) of 74 patients without clinical evidence of brain involvement, CT revealed cerebral metastases; this suggests that a staging CT scan might be useful on patients with diffuse or advanced local extracranial disease prior to definitive therapy.
 ...
PMID:Cranial computed tomography of malignant melanoma. 677 62

A subset of 10-20% of patients under continuous BRAF inhibitor monotherapy achieve long-term progression-free and overall survival. Definitive criteria for the safe cessation of BRAF inhibitor monotherapy in treatment-responsive melanoma patients are lacking. We report a patient who remained in complete remission (CR) for 5 years under dabrafenib. The treatment was withdrawn because of concerns about cardiac toxicity. Four months thereafter the patient developed neurological symptoms, including diplopia and bilateral visual loss. Meningeal melanomatosis and parenchymal brain metastases were diagnosed. Extracerebral metastases were excluded. Reinduction of dabrafenib, combined with trametinib, led to the rapid relief of the neurological symptoms, and a partial remission was confirmed radiologically. Unfortunately, the response was not maintained and the patient died 9 months later. This observation demonstrates that discontinuation of BRAF inhibition can result in loss of disease control. On the basis of this observation, we suggest that BRAF-targeted therapy should be withdrawn only when the risks of continued treatment exceed the risk for disease relapse. However, future studies are urgently required to confirm and quantify the risk for rapid disease relapse following withdrawal of BRAF inhibitor monotherapy.
 ...
PMID:Meningeal melanomatosis following discontinuation of dabrafenib: implications for the maintenance of long-term complete remission. 2872 25